Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats

Neurobiology of Disease
F LiMartin J Stevens

Abstract

Increased oxidative stress is implicated in the pathogenesis of diabetic peripheral neuropathy (DPN). However, the efficacy of antioxidant therapy on DPN complicating type 2 diabetes remains unexplored. We therefore determined the ability of the antioxidant taurine to reverse deficits of hind limb sciatic motor and digital sensory nerve conduction velocity (NCV), nerve blood flow (NBF), and sensory thresholds in hyperglycemic Zucker diabetic fatty (ZDF) rats. Experimental groups comprised lean nondiabetic (ND), ND treated with taurine (ND + T), untreated ZDF diabetic (D), and D rats treated with taurine (D + T). Compared to ND rats, 23%, 15% and 56% deficits of motor NCV, sensory NCV and NBF, respectively as well as thermal and mechanical hyperalgesia were reversed by taurine. An 84% deficit of dorsal root ganglion neuron calcitonin gene-related peptide in D rats was prevented by taurine. In summary, the antioxidant taurine reverses neurological and neurovascular deficits in experimental type 2 diabetes.

References

Jan 1, 1983·Japanese Heart Journal·N Kohashi, R Katori
Jul 13, 1995·The New England Journal of Medicine·J PartanenM Uusitupa
Jan 5, 2001·Amino Acids·W Abebe, M S Mozaffari
Dec 7, 2002·Diabetes/metabolism Research and Reviews·Yuichi MurakawaAnders A F Sima
May 6, 2004·American Journal of Physiology. Endocrinology and Metabolism·Martin J StevensAnders A F Sima
Apr 15, 2008·Trends in Endocrinology and Metabolism : TEM·R H Unger

❮ Previous
Next ❯

Citations

Feb 8, 2008·Current Diabetes Reports·Nigel A Calcutt, Miroslav Misha Backonja
Oct 1, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Irina G Obrosova
Sep 3, 2011·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Jayadave Shakher, Martin J Stevens
Apr 13, 2013·Physiology Journal·Elena G Zotova, Joseph C Arezzo
Jan 1, 2014·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Randhir SinghNavpreet Kaur
Feb 24, 2009·Canadian Journal of Physiology and Pharmacology·Stephen W SchafferMahmood Mozaffari
Nov 16, 2011·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Peng YaoBai-Shan Wu
Aug 28, 2010·Expert Opinion on Emerging Drugs·Abd A TahraniMartin J Stevens
Dec 22, 2015·The Journal of Pain : Official Journal of the American Pain Society·Ryan B GriggsBradley K Taylor
Jul 12, 2008·Pharmacology & Therapeutics·James L EdwardsEva L Feldman
Jul 24, 2007·European Journal of Pharmacology·Viktor R DrelIrina G Obrosova
Apr 22, 2008·Neurobiology of Disease·James W RussellEva L Feldman
Dec 25, 2009·Fundamental & Clinical Pharmacology·Amteshwar Singh JaggiNirmal Singh
May 23, 2012·Pharmacology, Biochemistry, and Behavior·Gema VeraRaquel Abalo
Mar 12, 2008·Diabetes·Valentine BrusseeDouglas W Zochodne
Jun 25, 2016·European Journal of Pain : EJP·N PaniaguaM I Martín Fontelles
Mar 2, 2018·Amino Acids· Inam-U-LlahZulfiqar Ahmed
Feb 24, 2018·Pharmacological Reports : PR·Anil KumarArti Singh
Jun 29, 2007·American Journal of Physiology. Renal Physiology·Jau-Shyang HuangMin-Shyang Hsu
Jul 26, 2017·Journal of Molecular Neuroscience : MN·Gui-Lian NiZhong-Min Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.